@ObsvRetardation I took it for real too but had to check, it seemed a little too far, even for novo. It's by Aktieland... relentless nvo pusher with the dummest takes
@GilaMonstrum That h2h really was a huge own goal.
It seems many novel therapies will be inferior to TZP (not an expert)... They still keep the development going. Is it about cost/benefit? Or do they aim for other indications?